8-K: Zomedica Q2 Revenue Up 14% to $7M, Gross Margin 67%

Zomedica Corp. announced strong second quarter 2025 financial results, with revenue increasing 14% year-over-year to $7.0 million, driven by robust growth in diagnostic and therapeutic product sales.

Summary

• Revenue for the second quarter of 2025 grew by 14% to $7.0 million, compared to $6.1 million in the second quarter of 2024.
• This marks the 18th consecutive quarter of record year-over-year revenue.
• Gross margin for the quarter was 67%.
• Diagnostics segment revenue, including TRUFORMA, TRUVIEW, and VETGuardian products, was $0.8 million, an 86% increase over Q2 2024.
• Therapeutic Device segment revenue, comprising PulseVet and Assisi products, was $6.2 million, up 8% from Q2 2024.
• Consumable revenues grew to $5.3 million, up 21% over Q2 2024, driven by TRUFORMA adoption and PulseVet trode sales.
• Capital revenues were $1.7 million, flat compared to Q2 2024.
• Total operating expenses were $12.7 million, a significant reduction from $29.4 million in Q2 2024, which included a $16.0 million non-cash impairment charge.
• Excluding the impairment, operating expenses decreased $0.7 million or 5% from an adjusted $13.4 million in Q2 2024.
• Research and development expenses increased 25% to $1.9 million.
• Selling and marketing expenses increased 19% to $4.6 million due to increased sales headcount and commissions.
• General and administrative expenses decreased 23% to $6.2 million, primarily due to non-recurrence of special meeting fees and lower salary expenses.
• Net loss for the quarter was $7.4 million, compared to $23.9 million (including impairment) in Q2 2024.
• Adjusted Non-GAAP EBITDA loss was $5.5 million, compared to $5.2 million in Q2 2024.
• The company held $59.1 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2025.
• As of June 30, 2025, there were 979,949,668 common shares issued and outstanding.
• A national Equine Asthma registry was launched to accumulate data for expanded PulseVet system usage.
• Enhanced TRUFORMA T4 assay and a VetGuardian onboarding app were recently launched.

Sentiment

Score: 7

Explanation: The company demonstrates strong top-line growth, particularly in high-margin diagnostic and consumable segments, and maintains a healthy cash position. While still operating at a net loss and a slightly increased adjusted EBITDA loss, the underlying operational metrics and strategic initiatives suggest positive momentum and future potential in the veterinary health market.

Positives

• Revenue grew 14% year-over-year to $7.0 million, marking the 18th consecutive quarter of year-over-year revenue growth.
• Achieved a strong gross margin of 67% for the quarter.
• Diagnostics segment revenue surged 86% year-over-year, driven by accelerating adoption of the TRUFORMA platform and expanded assay menu.
• Total Consumable sales increased 21% year-over-year, indicating a growing base for recurring revenue.
• International sales grew 13% compared to the second quarter of 2024.
• Operating expenses (excluding a non-cash impairment charge) decreased by $0.7 million or 5% year-over-year.
• Maintained a strong liquidity position with $59.1 million in cash, cash equivalents, and available-for-sale securities.
• Successfully launched new initiatives including a national Equine Asthma registry, an enhanced TRUFORMA T4 assay, and a VetGuardian onboarding app.

Negatives

• Reported a net loss of $7.4 million for the second quarter of 2025.
• Adjusted Non-GAAP EBITDA loss slightly increased to $5.5 million from $5.2 million in the prior year quarter.
• Research and development expenses increased by 25% year-over-year.
• Selling and marketing expenses increased by 19% year-over-year.
• Capital revenues remained flat compared to the second quarter of 2024.

Risks

• Uncertainty regarding the outcome of clinical studies.
• The application of generally accepted accounting principles is highly complex and involves many subjective assumptions, estimates, and judgments.
• Uncertainty as to whether strategies and business plans will yield the expected benefits.
• Uncertainty regarding the timing and results of development work, verification, and validation studies.
• Uncertainty concerning the timing and results of commercialization efforts, including international expansion and the cost of developing an internal sales force.
• Uncertainty about the ability to realize anticipated growth opportunities from acquisitions.
• Uncertainty regarding the ability to supply products in response to customer demand.
• Supply chain risks, including those associated with tariff changes.
• Uncertainty about the likelihood and timing of any required regulatory approvals, and the availability and cost of capital.
• Challenges in identifying, developing, and achieving commercial success for new products and technologies.
• Risk of veterinary acceptance of products and continued purchase of consumables following adoption of capital equipment.
• Competition from related products in the market.
• The level of expenditures necessary to maintain and improve the quality of products and services.
• Impact of changes in technology and changes in laws and regulations.
• Ability to secure and maintain strategic relationships.
• Dependence on strategic partners to perform their obligations under commercial agreements, including product manufacturing.
• Risks pertaining to permits and licensing.
• Intellectual property infringement risks.
• Risks related to any required clinical trials and regulatory approvals.
• Risks concerning the safety and efficacy of products and their use.
• Challenges in intellectual property protection.
• Other risk factors disclosed in SEC filings and under the company's profile on SEDAR+.

Future Outlook

Management expects to roll out additional enhancements to the VetGuardian and TRUVIEW platforms during the upcoming quarter. The company believes its current momentum and strong balance sheet position it to aggressively execute its strategy to drive accelerated adoption of its innovative portfolio globally, further supporting a foundation for recurring sales revenue.

Management Comments

• "We are very pleased with the 14% growth attained in the second quarter as we posted record year-over-year revenue for the 18th straight quarter." Larry Heaton, Chief Executive Officer.
• "Bolstered by continued and robust usage of our therapeutic products, including our PulseVet and Assisi products, and the continued growth and adoption of our diagnostic products, including our expanding TRUFORMA platform, we were able to deliver the strongest second quarter in company history." Larry Heaton, Chief Executive Officer.
• "Through further expansion of our portfolio and the continued optimization of our commercial organization, we are seeing the positive impact in both placements and consumable usage as evidenced by 86% growth in our Diagnostic segment and 21% growth in total Consumable sales year-over-year." Larry Heaton, Chief Executive Officer.
• "We believe this growth and the model in which these sales are generated further supports a foundation for recurring sales revenue in the future." Larry Heaton, Chief Executive Officer.
• "International sales continue to grow, with sales up 13% compared to the second quarter of 2024, driven by a combination of organic growth and orders from new distributor partners." Larry Heaton, Chief Executive Officer.
• "We are particularly pleased with the success of recent initiatives aimed at expanding our coverage and extending the use of our suite of products." Larry Heaton, Chief Executive Officer.
• "We expect to roll out additional enhancements to our VetGuardian and TRUVIEW platforms during the upcoming quarter." Larry Heaton, Chief Executive Officer.
• "Based on the momentum we have created through the second quarter of the year, and supported by the strength of our balance sheet, we believe that we are well positioned to aggressively execute on our strategy to drive the accelerated adoption of our innovative portfolio on a global scale." Larry Heaton, Chief Executive Officer.

Industry Context

Zomedica operates in the veterinary health sector, focusing on point-of-care diagnostic and therapeutic products for equine and companion animals. The reported growth in diagnostics (86%) and consumables (21%) suggests a positive trend in veterinary practices adopting advanced technologies and increasing recurring revenue streams, aligning with a broader industry shift towards specialized and high-tech animal care. The company's focus on international expansion and product enhancements indicates a strategic effort to capture a larger share of the estimated $2 billion U.S. total addressable market and beyond, positioning itself within a growing segment of the animal healthcare industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark Zomedica's performance against industry standards. It mentions a total addressable market in the U.S. exceeding $2 billion for its suite of products, but no direct competitive comparisons are made.

Stakeholder Impact

• Shareholders: Positive revenue growth, strong gross margins, and healthy liquidity could indicate improving financial health and future value creation. The continued net loss and slightly increased adjusted EBITDA loss might be a concern for short-term profitability.
• Employees: Increased headcount in the sales department and buildup of internal R&D capabilities suggest job stability and growth opportunities in those areas, though G&A saw lower salary and related expenses due to recent headcount actions.
• Customers (Veterinarians): Enhanced products (TRUFORMA T4 assay, VetGuardian onboarding app) and new initiatives (Equine Asthma registry) aim to improve workflow, provide better, faster, and more accurate performance, and support top-tier care, potentially increasing satisfaction and adoption.
• Suppliers: Increased product demand, especially for consumables, could lead to more business for suppliers.
• Creditors: Strong liquidity of $59.1 million indicates a healthy balance sheet, reducing credit risk.

Next Steps

• Roll out additional enhancements to VetGuardian and TRUVIEW platforms during the upcoming quarter.
• Continue to identify gaps in market offerings, including upgrading and enhancing current products to address changing needs and provide better, faster, and more accurate performance.
• Aggressively execute on the strategy to drive accelerated adoption of the innovative portfolio on a global scale.
• Host the Fourth Friday at Four Webinar on Friday, August 22, 2025, at 4:00 PM ET, to review and discuss second quarter financial performance.

Key Dates

Recommendation

Zomedica shows promising revenue growth, especially in its diagnostic and consumable segments, coupled with strong gross margins and a healthy cash balance. This indicates operational strength and market adoption of its products. However, the company is still operating at a net loss, and adjusted EBITDA loss slightly increased, suggesting profitability remains a challenge despite cost reduction initiatives. The increased R&D and S&M expenses are investments for future growth but contribute to current losses. Given the positive operational momentum balanced against continued unprofitability, a "hold" recommendation is appropriate for investors to observe if the growth translates into sustainable profitability.

Keywords

Zomedica, ZOMDF, veterinary health, animal health, diagnostic products, therapeutic products, PulseVet, Assisi, TRUFORMA, TRUVIEW, VetGuardian, VETIGEL, Q2 2025 results, financial results, revenue growth, gross margin, point-of-care, equine, companion animals